等待開盤 12-13 09:30:00 美东时间
+0.015
+0.21%
今日重点评级关注:Chardan Capital:维持Senti Biosciences"买入"评级,目标价从12美元升至13美元;Guggenheim:维持Praxis Precision Medicine"买入"评级,目标价从540美元升至760美元
12-10 10:33
Barclays analyst Glen Santangelo initiates coverage on Bausch Health Companies (NYSE:BHC) with a Equal-Weight rating and announces Price Target of $8.
12-09 23:29
加密货币交易所CNCK飙升140%,收购加密货币经纪公司Aplo拟进军欧洲市场;矿产勘探公司NFGC大涨18%,贵金属市场多头情绪浓厚,白银价格再创历史新高>>
12-02 15:05
Bausch Health shares are trading higher after the company announced its global ...
12-01 23:45
Carl Icahn's hedge fund Q3 portfolio reshuffle: $9.14B, concentrated, contrarian. Walked away from Bausch Health, added EchoStar.
11-17 21:59
Carl Icahn's empire, IEP, has collapsed 80% due to Hindenburg's short-selling attack. Icahn's net worth is down 75%.
11-06 21:21
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Bausch Health业绩会实录,以下是第三季度财务业绩回顾摘要: ## 1. 财务业绩 **整体表现:** - 合并营收:26.81亿美元,同比增长7%(报告基础)、5%(有机增长) - 调整后EBITDA:9.86亿美元,同比增长8% - 调整后经营现金流:5.08亿美元 **Bausch Health(剔除Bausch + Lomb):** - 营收:14亿美元,同比增长7%(报告基础)、5%(有机增长) - 调整后EBITDA:7.73亿美元,同比增长7%(包含8100万美元IPR&D费用) - 剔除IPR&D费用后,调整后EBITD
10-31 12:37
Bausch Health shares are trading higher after the company reported better-than-...
10-30 04:33
Bausch Health Companies (NYSE:BHC) raises FY2025 sales outlook from $10.000 billion-$10.250 billion to $10.050 billion-$10.250 billion vs $10.141 billion estimate.
10-30 04:09
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11